Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Shares in Danish pharmaceuticals giant Novo Nordisk (NOVO-B.CO, NVO) have continued to come under pressure amid competition in the weight-loss drug space, while UK health officials have launched a ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

The Semaglutide Market, valued at USD 28.43 Billion in 2024, is anticipated to reach USD 93.60 Billion by 2035, growing at a CAGR of 10.47%. Growth drivers include the rising prevalence of ...

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

The $160 billion fund behind Ozempic-maker Novo Nordisk A/S says President Donald Trump's tariff war has created so much economic ... very important market for all of our investments," he ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...